Cargando…
Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib
BACKGROUND: The T790M mutation of epithelial growth factor receptor (EGFR) is a major cause of the acquired resistance to EGFR tyrosine kinase inhibitor (EGFR-TKIs) treatment for lung cancer patients. The Hippo pathway effector, TAZ, has emerged as a key player in organ growth and tumorigenesis, inc...
Autores principales: | Xu, Wei, Wei, Yunyan, Wu, Shuangshuang, Wang, Yun, Wang, Zhen, Sun, Yu, Cheng, Steven Y, Wu, Jianqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429831/ https://www.ncbi.nlm.nih.gov/pubmed/25973173 http://dx.doi.org/10.1186/2045-3701-5-7 |
Ejemplares similares
-
TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription
por: Yuan, Weiwei, et al.
Publicado: (2019) -
Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
por: Wang, Yanyan, et al.
Publicado: (2023) -
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Zhang, Xiaoying
Publicado: (2021) -
Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis
por: Wang, Haichuan, et al.
Publicado: (2020) -
The effector of Hippo signaling, Taz, is required for formation of the micropyle and fertilization in zebrafish
por: Yi, Xiaogui, et al.
Publicado: (2019)